摘要
人类非洲锥虫病(HAT)是一种源自撒哈拉以南的容易被忽视的疾病,通常如果未得到治疗会致死。它是由寄生虫布氏锥虫引起并由苍蝇传播。目前治疗HAT的药物很少且药效低,此外这些药物不断产生耐药性。在过去的25年,HAT的治疗缓慢,因此对能够治疗这些疾病的新药的需要不断增长。本文对HAT药物发现提供了一个简短的综述,重点是过去4年报道有潜力发展为抗HAT剂的新的分子的研究。药物发现的方法已经被归为3个关键领域:已知的抗睾丸激素剂、靶向筛选、表型筛选的新分子。
关键词: 人体非洲锥虫病、布氏锥虫、抗睾丸激素、药物发现、表型筛选、靶向筛选
Current Medicinal Chemistry
Title:A Brief Review of Drug Discovery Research for Human African Trypanosomiasis
Volume: 24 Issue: 7
关键词: 人体非洲锥虫病、布氏锥虫、抗睾丸激素、药物发现、表型筛选、靶向筛选
摘要: Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub- Saharan Africa, is usually fatal if left untreated. It is caused by the parasite Trypanosoma brucei, and is spread by the tsetse fly. The drugs currently available to treat HAT are few, and limited in efficacy. Furthermore, resistance towards these drugs is beginning to grow. In the last 25 years, only one advance has been made into HAT treatment and consequently, there is an increasing need for new drugs to be sought that are able to effectively treat this disease. This review provides a brief overview of drug discovery research for HAT, focusing on research published in the last four years, identifying new molecules with the potential to be developed into anti-HAT agents. The methods of drug discovery have been grouped into three key areas; new molecules inspired by known antitrypanosomal agents, target-based screening, and phenotypic screening.
Export Options
About this article
Cite this article as:
A Brief Review of Drug Discovery Research for Human African Trypanosomiasis, Current Medicinal Chemistry 2017; 24 (7) . https://dx.doi.org/10.2174/0929867324666170120160034
DOI https://dx.doi.org/10.2174/0929867324666170120160034 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy The Basement Membrane Zone in Asthma
Current Respiratory Medicine Reviews Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design Multi-Objective Optimization Methods in De Novo Drug Design
Mini-Reviews in Medicinal Chemistry Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead
Letters in Drug Design & Discovery Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Fatty Acid-Binding Proteins at a Glance
Protein & Peptide Letters Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Mini-Reviews in Medicinal Chemistry Current Understanding of Polymyxin B Applications in Bacteraemia/ Sepsis Therapy Prevention: Clinical, Pharmaceutical, Structural and Mechanistic Aspects
Anti-Infective Agents in Medicinal Chemistry MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Current Pharmaceutical Design Ellagic Acid Increases Osteocalcin and Alkaline Phosphatase After Tooth Extraction in Nicotinic-Treated Rats
Current Pharmaceutical Design Application of Proteomics to Investigate Plant-Microbe Interactions
Current Proteomics Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice
Current Drug Metabolism Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters